byGrieve, Andy P.; Chow, Shien-Chung; Curram, John; Dawe, Stephen; Harnisch, Lutz O.; Henig, Noreen R.; Hung, Hsien Ming J.; Ivy, D. Dunbar; Kawut, Steven M.; Rahbar, Mohammad H.; Xiao, Shen; Wilkins, Martin R.
This article is from Pulmonary Circulation, volume 3.AbstractIn pulmonary hypertension, as in many other diseases, there is a need for a smarter approach to evaluating new treatments. The traditional randomized controlled trial has served medical science well, but constrains the development of treatments for rare diseases. A workshop was established to consider alternative clinical trial designs in pulmonary hypertension and here discusses their merits, limitations and challenges to... Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641733
This article is from Pulmonary Circulation, volume 2.AbstractThe survival rates of Chinese patients with idiopathic pulmonary arterial hypertension (IPAH) and familial pulmonary arterial hypertension (PAH) on conventional therapy at 1 and 3 years were 68.0% and 38.9%, respectively. Our aim was to update recent knowledge on the demographics, clinical course, hemodynamic features, disease management, and survival of adult patients with IPAH. This retrospective and observational study was... Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487306